Skip to content
OpenCapital
Get started

SION SION Business Segments — External research and development expense

Similar metrics at other companies

Travere Therapeutics, Inc. logo
TVTXReportable Segment — External research and development
$27.73M+24.0%
ImmunityBio, Inc. logo
IBRXReportable Segment — External research and development expense (including amounts with related parties)
$20.08M+264%
Viridian Therapeutics, Inc. logo
VRDNReportable Segment — Segment research and development expense
$71.74M+1.0%
Travere Therapeutics, Inc. logo
TVTXReportable Segment — Other research and development
$4.84M+9.2%
Zymeworks logo
ZYMEReportable Segment — Other research and development expense
$5.63M+3.1%
Agios Pharmaceuticals logo
AGIOReportable Segment — R&D
$23.91M+12.1%

Other financials

Income statement

See full
Operating income-$29.6M-50.6%
Net income-$26.8M-62.5%
EPS (diluted)-$0.60+3.2%

Balance sheet

See full
Cash & equivalents$64.3M-23.2%
Total debt$8.4M-11.8%
Total equity$288.2M-18.1%
Total assets$305.0M-17.5%

Cash flow

See full
Operating cash flow-$21.8M-34.1%
CapEx--100%
Free cash flow-$21.8M-33.4%

Valuation

See full
Market cap$1.8B—
Enterprise value$1.74B—

Returns & leverage

See full
Return on equity-26.7%—
Debt / equity0×0.0×
Current ratio22.6×-6.1×

Where this comes from

Reported directly by SION in its filing.

Tagged under the XBRL concept sionna:ExternalResearchAndDevelopmentExpense.

The official record: SION’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SION's business segments — external research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SION's business segments — external research and development expense?
SION (SION) reported business segments — external research and development expense of $12.93M in Q1 2026.
How has SION's business segments — external research and development expense changed year-over-year?
SION's business segments — external research and development expense increased by 29.6% year-over-year, from $9.98M to $12.93M.
What does business segments — external research and development expense mean?
Represents the direct costs incurred by a business segment for outsourced research and development activities, including contract research organizations and external laboratory services. This metric tracks the financial commitment to external innovation and clinical development pipelines essential for product advancement. Monitoring this helps investors assess the intensity of external investment in the company's core therapeutic research.